Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

A potential biomarker for anti-PD-1 immunotherapy

Nature Medicine volume 24, pages 123–124 (2018)Cite this article

Subjects

A recent study identifies an immune cell type known as classical monocytes in the peripheral blood as a potential biomarker for response to anti-PD-1 immune checkpoint therapy in metastatic melanoma.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Identification of a potential biomarker of response to anti-PD-1 therapy.

Marina Corral Spence/Springer Nature

References

  1. Sharma, P. & Allison, J.P. Cell 161, 205–214 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Sharma, P., Hu-Lieskovan, S., Wargo, J.A. & Ribas, A. Cell 168, 707–723 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Larkin, J. et al. N. Engl. J. Med. 373, 23–34 (2015).

    PubMed  PubMed Central  Google Scholar 

  4. Wolchok, J.D. et al. N. Engl. J. Med. 377, 1345–1356 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Michot, J.M. et al. Eur. J. Cancer 54, 139–148 (2016).

    Article  CAS  PubMed  Google Scholar 

  6. Krieg, C. et al. Nat. Med. 24, 144–153 (2018).

    Article  CAS  PubMed  Google Scholar 

  7. Sharma, P. Cancer J. 22, 68–72 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Le, D.T. et al. Science 357, 409–413 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Gao, J. et al. Nat. Med. 23, 551–555 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Zarour, H.M. Clin. Cancer Res. 22, 1856–1864 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Hanna, R.N. et al. Science 350, 985–990 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Romano, E. et al. Proc. Natl. Acad. Sci. USA 112, 6140–6145 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

    Sangeeta Goswami

  2. Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

    Sreyashi Basu & Padmanee Sharma

Authors
  1. Sangeeta Goswami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sreyashi Basu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Padmanee Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Padmanee Sharma.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Goswami, S., Basu, S. & Sharma, P. A potential biomarker for anti-PD-1 immunotherapy. Nat Med 24, 123–124 (2018). https://doi.org/10.1038/nm.4489

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.4489

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer